SIME builds AI-powered point-of-care diagnostics for intensive care. Starting with the earliest and most critical decision of life: whether a newborn’s lungs are ready to breathe.

Our platform analyses small samples of gastric aspirate in the NICU, using spectroscopy and AI to detect biochemical signatures of lung maturity within minutes of birth – hours before symptoms or deterioration appear. This gives clinicians objective, actionable insight at the exact moment treatment decisions matter most.

Compact, reagent-free, and designed for real-world NICU and ICU workflows, SIME delivers fast, precise, and clinically meaningful results that support better triage, earlier treatment, and fewer unnecessary admissions. Reducing risk for patients and cost for hospitals.

This is a new category of ICU diagnostics: early biochemical screening, powered by AI, built for critical care.